Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Man Max 99 years
Sanofi-aventis
Update Il y a 4 ans
Bioavailability study with two formulations of Clopidogrel in young healthy men
To compare the bioavailabilty of clopidogrel administered as 75 mg Plavix® tablet to that of 75 mg of clopidogrel in drinkable solution, after single oral administration, in fasting state, to normal h...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Sanofi Pasteur Limited
Update Il y a 4 ans
One-, Three-, Five-, Eight- and Ten-Year Data on the Long- Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adults and Adolescents
To describe the antibody levels for tetanus, diphtheria and pertussis at 1 year, 3 years, 5 years, 8 years and 10 years after vaccination with Tdap Vaccine.
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
A placebo-controlled, double blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter (AF/AFL)
To assess the efficacy of dronedarone in preventing cardiovascular hospitalizations or death from any cause in a population of high risk patients with Atrial Fibrillation/Atrial FLutter (AF/AFL).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-aventis U.S. Inc
Update Il y a 4 ans
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 μg administered either in a once-daily in the morning regimen (160 μg qd AM) for 16 weeks or in a 160 μg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 μg bid) for 4 weeks, or in an 80 μg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids
To investigate the efficacy, compared to placebo, of ciclesonide at a daily dose of 160 μg administered either in a once-daily in the morning regimen (160 μg qd AM) for 16 weeks or in a 160 μg qd AM r...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
Estudio aleatorizado, doble ciego, en el que se comparan los efectos de un régimen de clopidogrel durante 3 meses en combinación con AAS durante el primer mes, frente a AAS en monoterapia, para el tratamiento agudo de pacientes con AIT o ictus menor. Randomized, double-blind trial comparing the effects of a 3-month clopidogrel regimen, combined with ASA during the first month, versus ASA alone for the acute treatment of patients with TIA or minor stroke
Evaluar los efectos de un régimen de clopidogrel durante 3 meses, con dosis de carga de 300 mg seguida de 75 mg/día, en combinación con 75 mg/día de AAS durante el primer mes, frente a monoterapia con...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
Estudio abierto y multicéntrico, de cincuenta y dos semanas de duración, para evaluar la seguridad y tolerabilidad a largo plazo de SR58611A 350 mg cada 12 horas en pacientes con trastorno depresivo mayor
Evaluar la seguridad y tolerabilidad a largo plazo de SR58611A en pacientes con trastorno depresivo mayor (MDD).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur
Update Il y a 4 ans
Immunogenicity and Lot-to-Lot Consistency Study of a Quadrivalent Influenza Vaccine in Adult and Elderly Subjects
• Immunogenicity: Lot Consistency To demonstrate equivalence of immune response induced by the 3 different industrial lots of Quadrivalent Influenza Vaccine (QIV) for each strain • Immunogenicity: N...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
PROSELICA : Essai de phase 3, randomisé comparant l’efficacité de deux doses de cabazitaxel associées à de la prednisone, chez des patients ayant un cancer de la prostate métastatique résistant à la castration. [essai clos aux inclusions]
L’objectif de cet essai est de comparer l’efficacité de deux dosages de cabazitaxel administré en association avec de la prednisone, chez des patients ayant un cancer de la prostate métastatique et ré...
Country
France
organs
Prostate
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Sanofi-Aventis TED10219 : Essai de phase 1 en escalade de dose évaluant la tolérance d’un traitement par AVE9633 chez des patients ayant une leucémie myéloïde aigüe. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
An open label, dose-escalation safety and pharmacokinetic study of AVE9633 administered as a single agent by intravenous infusion on day 1, day 4 and day 7 of a 4-week cycle in patients with relapsed ...
Country
France
organs
Leucémies aiguës
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman Max 99 years
Sanofi Pasteur
Update Il y a 4 ans
Immunogenicity and Safety of Quadrivalent Influenza Vaccine (VaxigripTetra™) in Pregnant Women
Immunogenicity To demonstrate the non-inferiority of immunogenicity response induced by one dose of VaxigripTetra compared with one dose of Vaxigrip in pregnant women. Safety To describe the sa...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
12
13
14
15
16
17
18
19
20
21